China will ban the import of DNA sequencers from San Diego-based Illumina, an apparent response to additional US tariffs.
Edenbridge Pharmaceuticals received this year's first untitled letter from the FDA's drug promotion office over misleading ...
PepGen is 'temporarily pausing' a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday ...
DOGE says that it has terminated the leases of 30 FDA offices and buildings, including a 52,000 square-foot St. Louis-based ...
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, ...
Teladoc faces flat revenue forecasts through 2025, prompting business model shifts. Analysts are hopeful Teladoc’s efforts ...
A special committee of 23andMe’s board rejected CEO Anne Wojcicki’s latest offer to take the company private.
Pfizer CEO Bourla says company can shift operations from foreign sites to US manufacturing network to counter Trump's tariffs ...
UnitedHealthcare's Surest plan sees rapid growth with 25% of large customers adopting it as employers seek cost-effective ...
NIH-funded trial at Mass Eye and Ear shows stem cell transplants improved corneal damage in 13 of 14 patients, led by Dr. Ula ...
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s ...
The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital's shell company Concentra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback